Sarah Leary
0000-0003-0225-6184
Publication & Citation Trends
Publications
0 total
Therapeutic HDAC inhibition in hypermutant diffuse intrinsic pontine glioma OA
Cited by 12
Semantic Scholar
Infantile ZFTA Fusion–Positive Tumor of the Posterior Fossa: Molecular Tumor Board OA
Cited by 1
Semantic Scholar
The "SEED" Study: The Feasibility of Selecting Patient-Specific Biologically Targeted Therapy with Sorafenib, Everolimus, Erlotinib or Dasatinib for Pediatric and Young Adult Patients with Recurrent or Refractory Brain Tumors. OA
Cited by 3
Semantic Scholar
Mutations of the DNA repair gene PNKP in a patient with microcephaly, seizures, and developmental delay (MCSZ) presenting with a high-grade brain tumor OA
Cited by 2
Semantic Scholar
Matrix Hyaluronic Acid and Hypoxia Influence a CD133+ Subset of Patient-Derived Glioblastoma Cells OA
Cited by 12
Semantic Scholar
Optimal therapeutic targeting by HDAC inhibition in biopsy-derived treatment-naïve diffuse midline glioma models. OA
Cited by 59
Semantic Scholar
Crosstalk between microglia and patient-derived glioblastoma cells inhibit invasion in a three-dimensional gelatin hydrogel model OA
Cited by 33
Semantic Scholar
Molecularly Targeted Treatments for NF1-Mutant Diffuse Intrinsic Pontine Glioma.
Cited by 2
Semantic Scholar
Everolimus improves the efficacy of dasatinib in PDGFRα-driven glioma. OA
Cited by 60
Semantic Scholar
Research Topics
Glioma Diagnosis and Treatment
(197)
Neuroblastoma Research and Treatments
(79)
Cancer Genomics and Diagnostics
(28)
Chromatin Remodeling and Cancer
(24)
Brain Metastases and Treatment
(20)
Affiliations
Indiana University Health
Seattle Children's Hospital
St. Jude Children's Research Hospital
Nationwide Children's Hospital
Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa